The Cigna Group (CI) Q4 2025 earnings review
A Strong Finish to 2025, A Transition Year Ahead
Cigna delivered a solid Q4 beat, with Adjusted EPS rising 22% to $8.08 and full-year revenue growing 11%. However, the narrative has shifted aggressively to 2026 as a 'transition year.' While the company beat FY25 targets, the FY26 guidance implies a contraction in total Operating Income ($8.0B in FY25 to ~$7.95B in FY26). The culprit is Evernorth, where income is guided to fall due to the strategic pivot to a 'rebate-free' pharmacy model and contract renewals. EPS is saved only by buybacks.
🐂 Bull Case
The Healthcare segment is stepping up as the profit engine. Q4 adjusted income surged 44%, and FY26 guidance projects at least $4.5B in income, significantly up from $4.15B in FY25, driven by improved margins and the exit of the lower-margin Medicare business.
Evernorth's Specialty and Care Services remains a powerhouse, with revenue up 14% and income up 9% in Q4. Biosimilar adoption (Humira, Stelara) continues to drive volume and affordability.
🐻 Bear Case
Evernorth is the company's largest profit center, and it is shrinking. FY26 guidance calls for 'at least $6.9B' in operating income, down from $7.2B in FY25. The shift to rebate-free models and contract repricing is a tangible headwind.
With operating income guided down year-over-year, the projected slight growth in EPS ($29.84 to >$30.25) is mathematically engineered through share repurchases rather than organic operational profit growth.
⚖️ Verdict: ⚪
Neutral. The company is executing a necessary but painful strategic pivot in its PBM business. While Cigna Healthcare is performing well, the earnings stagnation guided for FY26 removes short-term catalysts. Investors are effectively waiting for the 'rebate-free' model to stabilize in 2027.
Key Themes
Evernorth Margin Compression
The pivot to a rebate-free model is costly. Evernorth's pre-tax margin compressed to 3.5% in Q4 2025 from 4.0% a year ago. Furthermore, FY26 guidance implies a clear profit decline for the segment ($7.2B down to $6.9B). This 'transition' is not theoretical; it is actively eroding margins now.
Specialty & Care Services Momentum
This sub-segment remains the crown jewel of growth. In Q4, adjusted revenue grew 14% and operating income rose 9% to $1.03B. With biosimilar adoption accelerating, this unit effectively counters the weakness in the traditional Pharmacy Benefit Services side.
Medical Cost Ratio (MCR) Watch
Cigna Healthcare's MCR came in at 88.0% for Q4 2025, essentially flat vs 87.9% last year but seasonally high. For the full year, MCR ticked up to 84.4% from 83.2%. While guidance for FY26 (83.7%-84.7%) suggests stability, the floor is structurally higher than the 81-82% levels seen in prior years.
Cigna Healthcare Profitability
Despite the divestiture of the Medicare business causing a headline revenue drop (-16% in Q4), the profitability of the remaining commercial book is surging. Q4 Adjusted Income from Operations grew 44% YoY to $734M. This confirms the strategy to shed lower-margin government lines to focus on higher-margin commercial/specialty lines.
Shareholder Returns as EPS Bridge
The company repurchased 11.9 million shares for $3.6 billion in 2025. With operational income stalling in FY26, the guidance relies heavily on capital deployment (buybacks) to show any per-share growth. The dividend was also raised to $1.56 (+3%).
Other KPIs
Accelerating. Growth hit +10% YoY, continuing the momentum from Q3 (+10%) and Q2 (+11%). Strength was driven almost entirely by Evernorth (+17%), while Cigna Healthcare revenue contracted due to divestitures.
Improving. The expense ratio dropped significantly from 5.7% in Q4 2024. This operational discipline is critical to protecting the bottom line as gross margins in the PBM business compress.
Stable/Growing. Pharmacy customers increased 4% YoY (up from 118.3M), showing that despite the noise around PBM models, the company continues to win and retain volume.
Guidance
Reversing/Contracting. This guide is lower than the $8.014 billion achieved in FY25. This confirms that 2026 is an operational retraction year driven by the Evernorth transition.
Decelerating. Implies only ~1.4% growth vs FY25 ($29.84). This is a massive deceleration from the 10-14% long-term growth target management historically cites.
Decelerating. Implies growth of ~2% vs FY25's $275B. While base effects from divestitures play a role, this indicates a sharp slowdown in top-line expansion.
Reversing. Down from $7.22B in FY25. This is the mathematical drag on the entire enterprise for the coming year.
Key Questions
Evernorth Margin Floor
With Evernorth income guided down for FY26, have we reached the floor of the 'rebate-free' transition impact, or could contract implementation risks drag this into 2027?
Organic Growth vs. Buybacks
Given that consolidated operating income is guided to shrink in FY26, what is the path back to organic, operational profit growth that meets the 10-14% long-term target without relying solely on share repurchases?
MCR Structural Shift
FY26 MCR guidance (83.7-84.7%) is structurally higher than historical norms. Is this the new normal for the commercial book post-COVID and post-GLP-1 adoption?